Integra LifeSciences Q3 earnings beat estimates, but revenue falls short (IART:NASDAQ)

Integra LifeSciences (IART) reported Q3 Non-GAAP EPS of $0.59, beating estimates by $0.03, but revenue of $411.2M missed expectations by $0.9M. The company guided Q4 revenue to $413M–$433M, below consensus of $432.21M, and adjusted EPS to $0.61–$0.71.

Original reporting
Published Oct 21, 2026, 10:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IART
Bearish
high confidence
Mentioned
$IART
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The earnings beat and revenue miss provide fresh data for traders to adjust positions before the market opens.

02

Market read

First‑time earnings release with mixed results; likely influences short‑term price action.

03

What to watch

Potential cost‑control measures or upcoming product launches not disclosed may mitigate revenue concerns.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences released its Q3 earnings, marking the first public disclosure of these results.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Q3 non‑GAAP EPS of $0.59 beat estimates while revenue of $411.2M missed by $0.9M; Q4 revenue guidance of $413M‑$433M is below consensus.

Expected impact

likely modest pressure as investors price in the revenue shortfall despite earnings beat

Evidence & confidence

Revenue fell short of expectations, a key driver for valuation, while EPS beat offers limited upside; market typically reacts more to top‑line misses.

Market effects

Medical device sector may see slight pullback as a peer reports weaker revenue growth.

U.S. biotech/medical device stocks could experience modest volatility in early trading.

Limited to investors tracking earnings season; no broader macro impact.

Counterpoint

The EPS beat suggests operational efficiency; the stock could rebound if guidance is revised upward.

Key entities

  • Integra LifeSciences Holdings Corporation

    Medical device and surgical equipment manufacturer.

Related articles

$IARTMedAI 8/10

IART Q3 deep dive: Cincinnati disruption and Tissue Reconstruction challenges weigh on outlook

Integra LifeSciences (IART) reported Q3 operating margin of 4.6%, down from 9.9% YoY. Management cut full-year Adjusted EPS guidance to $2.35 midpoint, citing Cincinnati facility disruption and Tissue Reconstruction challenges. Neurosurgery growth offset some weaknesses. Debt refinancing improved liquidity, but higher interest expense is expected. Recovery from flood impact anticipated by mid-2027.